KALA BIO (KALA) Competitors $5.47 -0.23 (-4.04%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$5.48 +0.01 (+0.11%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. DMAC, IMRX, LFVN, LXEO, GLSI, LYEL, MOLN, THTX, CGEN, and IKTShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include DiaMedica Therapeutics (DMAC), Immuneering (IMRX), Lifevantage (LFVN), Lexeo Therapeutics (LXEO), Greenwich LifeSciences (GLSI), Lyell Immunopharma (LYEL), Molecular Partners (MOLN), Theratechnologies (THTX), Compugen (CGEN), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors DiaMedica Therapeutics Immuneering Lifevantage Lexeo Therapeutics Greenwich LifeSciences Lyell Immunopharma Molecular Partners Theratechnologies Compugen Inhibikase Therapeutics KALA BIO (NASDAQ:KALA) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Is KALA or DMAC more profitable? DiaMedica Therapeutics' return on equity of -61.35% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -369.29% -64.99% DiaMedica Therapeutics N/A -61.35%-55.53% Which has more risk and volatility, KALA or DMAC? KALA BIO has a beta of -1.88, indicating that its share price is 288% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Do insiders & institutionals hold more shares of KALA or DMAC? 24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 8.3% of KALA BIO shares are owned by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate KALA or DMAC? KALA BIO currently has a consensus price target of $13.00, suggesting a potential upside of 137.66%. DiaMedica Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 86.05%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, KALA or DMAC? DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BION/AN/A-$38.51M-$8.24-0.66DiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-6.72 Does the media favor KALA or DMAC? In the previous week, KALA BIO had 9 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 10 mentions for KALA BIO and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.89 beat KALA BIO's score of 0.18 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment KALA BIO Neutral DiaMedica Therapeutics Very Positive SummaryKALA BIO and DiaMedica Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.78M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.6620.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book2.717.568.145.54Net Income-$38.51M-$55.11M$3.24B$257.73M7 Day Performance-13.17%3.81%0.18%-0.08%1 Month Performance26.04%11.60%5.96%8.09%1 Year Performance-30.05%-2.11%26.24%13.02% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.8896 of 5 stars$5.47-4.0%$13.00+137.7%-28.1%$36.78MN/A-0.6630DMACDiaMedica Therapeutics1.1814 of 5 stars$3.61-1.7%$8.00+121.7%+20.1%$155.01MN/A-5.6520IMRXImmuneering3.3779 of 5 stars$4.22-2.7%$13.25+214.4%+242.6%$151.72MN/A-2.1560LFVNLifevantage4.2759 of 5 stars$12.03-2.8%$30.50+153.6%+102.6%$151.57M$200.16M17.45260News CoveragePositive NewsLXEOLexeo Therapeutics2.0204 of 5 stars$4.47-2.6%$16.60+271.4%-68.3%$149.87M$650K-1.3758GLSIGreenwich LifeSciences2.1436 of 5 stars$10.96-2.3%$39.00+255.8%-35.6%$146.54MN/A-8.703LYELLyell Immunopharma3.2501 of 5 stars$9.86+0.9%$15.00+52.2%-73.5%$145.92M$65K-0.39270News CoverageMOLNMolecular Partners3.0793 of 5 stars$3.61+1.5%$12.00+232.9%-43.5%$145.55M$2.23M-1.88180THTXTheratechnologiesN/A$3.16+0.2%N/A+103.9%$145.07M$85.87M-16.61140Earnings ReportCGENCompugen1.6068 of 5 stars$1.63-3.8%$4.00+146.2%-17.3%$145.02M$27.86M-10.1670Positive NewsIKTInhibikase Therapeutics1.2001 of 5 stars$1.94-3.0%$6.50+235.1%+20.8%$143.85MN/A-0.726 Related Companies and Tools Related Companies DiaMedica Therapeutics Competitors Immuneering Competitors Lifevantage Competitors Lexeo Therapeutics Competitors Greenwich LifeSciences Competitors Lyell Immunopharma Competitors Molecular Partners Competitors Theratechnologies Competitors Compugen Competitors Inhibikase Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALA Stock Alerts